OiDE Adjubilee, Daiichi Sankyo, National Institute of Biomedical Innnovation deal

Newco Adjubilee partnered with Daiichi and the institute to develop an undisclosed cancer immunotherapy, which Daiichi said is in the "early research stage." Daiichi will provide scientific support to the institute, which will conduct all research activities. At the end of the two-year collaboration, Daiichi has the option to acquire all shares of Adjubilee to continue development of the immunotherapy. If Daiichi exercises the option, the institute will be eligible for royalties...